Anthropic launches its own drug discovery programs to tackle diseases Big Pharma considers unprofitable
Quick Answer
Anthropic is initiating drug discovery programs targeting neglected diseases deemed unprofitable by Big Pharma.
Quick Take
Anthropic is initiating drug discovery programs targeting neglected diseases deemed unprofitable by Big Pharma. Novartis CEO Vas Narasimhan suggests AI could reduce development time from 12 years to 7-8 years and potentially double the success rate from 8% to 16%.
Key Points
- Anthropic targets neglected diseases overlooked by major pharmaceutical companies.
- AI could significantly shorten drug development timelines and improve success rates.
- Novartis estimates AI can cut development time from 12 years to 7-8 years.
- Potential success rate for drug development could rise from 8% to 16%.
Article Excerpt
From source RSS / original summaryAnthropic is launching its own drug development program for neglected diseases that the pharmaceutical industry considers unprofitable. Novartis CEO Vas Narasimhan thinks AI could cut development time from twelve years to seven or eight and double the success rate from 8 to 16 percent. The article Anthropic launches its own drug discovery programs to tackle diseases Big Pharma considers unprofitable appeared first on The Decoder.
Want this in your inbox every morning?
Daily brief at your local 8am — bilingual EN/中文, free.
More from The Decoder
See more →
An AI model programmed nonstop for 19 days on a single MirrorCode task that cost $2,600 to run
Epoch AI's MirrorCode benchmark reveals Claude Opus 4.7 as the leader with a 56% solve rate, reconstructing a 16,000-line toolkit in 14 hours. Despite this, all models tested struggle with the most complex tasks, highlighting limitations in current AI capabilities. The single task consumed $2,600 over 19 days, raising questions about cost-effectiveness in AI development.
